Innovation Empowers Global Progress | Dorra Pharma Wraps Up CPHI Frankfurt 2025 Successfully

发布时间： 2025-10-31 阅读：24次

分享

From October 28 to 30, 2025, Dorra Pharma made a remarkable presence at CPHI Frankfurt, accompanied by our global business team. As one of the premier events in the pharmaceutical industry, this year’s exhibition gathered top enterprises and innovators from across the globe. Dorra’s participation stood out, showcasing our advanced technologies, systematic capabilities, and global service philosophy, which drew significant recognition and interest from international partners.

At the exhibition, we highlighted our cutting-edge breakthroughs in complex synthesis technology, continuous flow manufacturing, enzyme-catalyzed processes, and peptide & small nucleic acid synthesis. These innovations demonstrate Dorra’s leadership in the development of high-barrier APIs. In addition, we presented a diverse array of core products and key R&D projects spanning therapeutic areas such as anti-infection, central nervous system disorders, and diabetes. This comprehensive display underscores Dorra’s unwavering commitment to advancing research and technology, fully aligned with our guiding philosophy: “Driving business through R&D, leading the future with innovation.”

Global partners praised Dorra’s technical expertise, leading to valuable discussions on joint development and customized process optimization. These conversations further solidified the strength of our in-house R&D platform and collaborative capabilities.

Dorra Pharma’s approach is built on a two-way empowerment service platform, enhancing connections between international clients and high-quality Chinese manufacturing resources. Throughout the exhibition, our team engaged in meaningful dialogues on supply chain optimization, continuous management, and risk mitigation. These discussions are laying the foundation for refining our global supply network, bolstering operational resilience, and enhancing service efficiency.

Another key highlight was Dorra’s licensing platform, which focuses on “two-way pharmaceutical preparation rights transactions.” By introducing mature overseas formulations and licensing promising domestic varieties, we are actively expanding our international pharmaceutical preparation network. Several overseas pharmaceutical enterprises expressed a strong interest in collaborating with Dorra, opening up exciting new opportunities in the global preparation market.

CPHI Frankfurt 2025 was not only an important platform for showcasing Dorra Pharma’s global brand; it was also a significant opportunity to deepen international cooperation and expand strategic partnerships. Moving forward, Dorra will continue to embrace our philosophy: “Innovation as the core driver, development through collaboration.” We are committed to advancing the high-quality development of the pharmaceutical industry and creating a healthier future for patients worldwide.